Dr. Kasim Diril is the leader of the IBG Gene Targeting and Transgenic Models Platform. The primary role of the platform is providing services to researchers particularly by developing genetically modified mouse models. However, several research projects involving mouse models (rare genetic diseases, liver disease) are running in parallel. One of these projects is the development of FAH/Rag2/Il2rg triple knockout (FRG TKO) mouse models for humanization of mouse livers. The project proposed for this program will utilize the FRG TKO mice for implantation and homing of patient tumours into the mouse liver. Other genetic tools will be explored that allow efficient humanization of the liver and immune system, with the final aim of creating a novel in vivo tool for research in personalized medicine and liver cancer.